Hemogenyx Pharmaceuticals PLC (LSE:HEMO) — Stock Price
Hemogenyx Pharmaceuticals PLC (LSE:HEMO) is currently trading at GBX642.50 GBX, up 1.18% today. Over the past 52 weeks, shares have ranged between GBX135.50 and GBX1545.00. This page tracks Hemogenyx Pharmaceuticals PLC's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Hemogenyx Pharmaceuticals PLC.
Hemogenyx Pharmaceuticals PLC (HEMO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hemogenyx Pharmaceuticals PLC's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hemogenyx Pharmaceuticals PLC Income Statement — Revenue, Profit & Earnings by Year
Hemogenyx Pharmaceuticals PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | GBX0.00 | GBX0.00 | GBX0.00 | GBX0.00 | GBX0.00 |
| Cost of Revenue | GBX639.28K | GBX645.68K | GBX2.60 Million | GBX283.65K | GBX350.72K |
| Gross Profit | GBX-639.28K | GBX-645.68K | GBX-2.60 Million | GBX-283.65K | GBX-350.72K |
| Research & Development | GBX236.72K | GBX90.63K | GBX402.94 | GBX37.58 | GBX83.66 |
| SG&A | GBX4.74 Million | GBX4.91 Million | GBX942.35K | GBX1.40 Million | GBX623.84K |
| Total Operating Expenses | GBX5.09 Million | GBX4.91 Million | GBX2.93 Million | GBX2.70 Million | GBX1.87 Million |
| Operating Income | GBX-5.73 Million | GBX-5.56 Million | GBX4.00 Million | GBX-2.70 Million | GBX-2.15 Million |
| EBITDA | GBX-4.71 Million | GBX-5.73 Million | GBX-3.42 Million | GBX-2.39 Million | GBX-1.96 Million |
| EBIT | GBX-5.35 Million | GBX-6.38 Million | GBX-3.99 Million | GBX-2.51 Million | GBX-2.06 Million |
| Interest Expense | GBX271.56K | GBX315.99K | GBX33.00 | GBX2.60 Million | GBX33.24K |
| Income Before Tax | GBX-5.63 Million | GBX-6.70 Million | GBX-3.99 Million | GBX-5.11 Million | GBX-2.10 Million |
| Income Tax Expense | — | GBX-5.82K | GBX361.16K | GBX2.41 Million | GBX20.44K |
| Net Income | GBX-5.62 Million | GBX-6.69 Million | GBX-3.98 Million | GBX-5.10 Million | GBX-2.08 Million |
Hemogenyx Pharmaceuticals PLC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hemogenyx Pharmaceuticals PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | GBX4.21 Million | GBX6.11 Million | GBX7.09 Million | GBX8.52 Million | GBX2.66 Million |
| Total Current Assets | GBX839.05K | GBX2.17 Million | GBX2.59 Million | GBX7.14 Million | GBX1.92 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX7.86K | GBX1.07K | GBX9.81K | GBX7.51K | GBX56.27K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | GBX797.13K | GBX268.74K |
| Goodwill | — | GBX28.68K | — | — | — |
| Total Liabilities | GBX3.36 Million | GBX3.32 Million | GBX3.85 Million | GBX352.84K | GBX1.79 Million |
| Total Current Liabilities | GBX1.16 Million | GBX652.09K | GBX748.41K | GBX352.84K | GBX1.78 Million |
| Long-term Debt | — | — | — | — | GBX0.00 |
| Net Debt | GBX2.46 Million | GBX1.70 Million | GBX890.08K | GBX-6.83 Million | GBX-184.17K |
| Total Stockholder Equity | GBX897.51K | GBX2.82 Million | GBX3.28 Million | GBX8.19 Million | GBX890.84K |
| Retained Earnings | GBX-35.58 Million | GBX-23.80 Million | GBX-17.11 Million | GBX-13.13 Million | GBX-8.04 Million |
Hemogenyx Pharmaceuticals PLC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hemogenyx Pharmaceuticals PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-4.12 Million | GBX-6.11 Million | GBX-2.91 Million | GBX-2.63 Million | GBX-1.80 Million |
| Capital Expenditures | GBX13.28K | GBX117.28K | GBX428.94K | GBX818.00K | GBX173.05K |
| Free Cash Flow | GBX-4.13 Million | GBX-6.22 Million | GBX-3.34 Million | GBX-3.45 Million | GBX-1.97 Million |
| Investing Cash Flow | GBX-24.90K | GBX-31.94K | GBX-420.25K | GBX-938.95K | GBX-169.68K |
| Financing Cash Flow | GBX3.08 Million | GBX4.45 Million | GBX-110.14K | GBX8.78 Million | GBX3.21 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX343.94K | GBX242.84 | GBX17.57K | GBX153.35K | GBX363.10K |
| Depreciation | GBX639.28K | GBX645.68K | GBX195.25K | GBX126.34K | GBX106.75K |
| Change in Cash | GBX-1.09 Million | GBX-1.29 Million | GBX-4.31 Million | GBX5.03 Million | GBX1.31 Million |
Hemogenyx Pharmaceuticals PLC Earnings History — EPS Actual vs. Analyst Estimates
Track Hemogenyx Pharmaceuticals PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 27, 2026 | — | — | — |
| Sep 25, 2025 | -1.42 | — | — |
| Apr 25, 2025 | -0.79 | 0.00 | — |
| Sep 27, 2024 | -0.92 | 0.00 | — |
| Apr 28, 2023 | 0.00 | 0.00 | — |
| Sep 29, 2022 | 0.00 | 0.00 | — |
| Apr 29, 2022 | 0.00 | 0.00 | — |
| Sep 30, 2021 | -0.01 | — | — |